
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
Q2 Solutions, a clinical trial laboratory services organization resulting from an IQVIA and Quest Diagnostics joint venture, announced its collaboration with the University of Texas Medical Branch to develop a novel assay for COVID-19 tests. Once a viable assay is developed, Q2 Solutions labs will produce it for use in clinical trials to determine the effectiveness of a COVID-19 vaccine.
For more information, click






